ATE406380T1 - Hiv-peptide aus konservierten regionen in gag p17 und deren anwendung z.b. in impfstoffen - Google Patents

Hiv-peptide aus konservierten regionen in gag p17 und deren anwendung z.b. in impfstoffen

Info

Publication number
ATE406380T1
ATE406380T1 AT01961444T AT01961444T ATE406380T1 AT E406380 T1 ATE406380 T1 AT E406380T1 AT 01961444 T AT01961444 T AT 01961444T AT 01961444 T AT01961444 T AT 01961444T AT E406380 T1 ATE406380 T1 AT E406380T1
Authority
AT
Austria
Prior art keywords
vaccines
gag
application
hiv peptides
preserved regions
Prior art date
Application number
AT01961444T
Other languages
English (en)
Inventor
Birger Soerensen
Original Assignee
Bionor Immuno As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bionor Immuno As filed Critical Bionor Immuno As
Application granted granted Critical
Publication of ATE406380T1 publication Critical patent/ATE406380T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • AIDS & HIV (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Extraction Or Liquid Replacement (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT01961444T 2000-09-04 2001-09-03 Hiv-peptide aus konservierten regionen in gag p17 und deren anwendung z.b. in impfstoffen ATE406380T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NO20004413A NO314588B1 (no) 2000-09-04 2000-09-04 HIV-peptider, antigener, vaksinesammensetning, immunoassay- testsett og en fremgangsmåte for å påvise antistoffer indusert av HIV

Publications (1)

Publication Number Publication Date
ATE406380T1 true ATE406380T1 (de) 2008-09-15

Family

ID=19911533

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01961444T ATE406380T1 (de) 2000-09-04 2001-09-03 Hiv-peptide aus konservierten regionen in gag p17 und deren anwendung z.b. in impfstoffen

Country Status (19)

Country Link
US (2) US7009037B2 (de)
EP (2) EP1322665B1 (de)
JP (2) JP2004508381A (de)
CN (2) CN1282656C (de)
AR (2) AR033998A1 (de)
AT (1) ATE406380T1 (de)
AU (3) AU2001282706B2 (de)
BR (1) BR0114036A (de)
CA (1) CA2421193A1 (de)
DE (1) DE60135564D1 (de)
EA (1) EA006308B1 (de)
ES (1) ES2312465T3 (de)
HU (1) HUP0303134A3 (de)
MY (1) MY136081A (de)
NO (1) NO314588B1 (de)
NZ (2) NZ524556A (de)
SK (1) SK287917B6 (de)
WO (1) WO2002020554A2 (de)
ZA (1) ZA200301740B (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1635876A (zh) 2000-02-04 2005-07-06 杜克大学 人免疫缺陷病毒疫苗
DE602006005686D1 (de) * 2005-08-26 2009-04-23 Novo Nordisk As Verfahren zur modifizierung eines makromolekularen systems
JP5021649B2 (ja) * 2005-08-26 2012-09-12 ノヴォ ノルディスク アクティーゼルスカブ 高分子システムを変性する方法
FI120376B (fi) * 2007-01-17 2009-09-30 Next Biomed Technologies Nbt O Menetelmä biomuokatun, korkean affiniteetin polypeptidin valmistamiseksi
FI120349B (fi) 2007-03-07 2009-09-30 Next Biomed Technologies Nbt O Menetelmä fuusiopolypeptidin valmistamiseksi
US8431153B2 (en) 2008-09-09 2013-04-30 Celebrity Biogens, Llc Bioactive composition for the treatment of the HIV/AIDS, method for manufacturing and using the same
WO2010045659A1 (en) 2008-10-17 2010-04-22 American Gene Technologies International Inc. Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules
US9910040B2 (en) 2012-07-09 2018-03-06 Sevident, Inc. Molecular nets comprising capture agents and linking agents
US9733242B2 (en) 2012-10-07 2017-08-15 Sevident, Inc. Devices for capturing analyte
FR2957933B1 (fr) * 2010-03-24 2012-04-27 Seppic Sa Vaccin vivant pour maladies aviaires
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
JP6294076B2 (ja) * 2011-01-06 2018-03-14 ビオノール イミュノ エーエスBionor Immuno As 多量体ペプチド
ES2667425T3 (es) 2011-06-10 2018-05-10 Oregon Health & Science University Glucoproteínas y vectores recombinantes de CMV
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
EP2586461A1 (de) 2011-10-27 2013-05-01 Christopher L. Parks Von einem eingehüllten Virus abgeleitete Virenpartikel
WO2013182661A1 (en) * 2012-06-06 2013-12-12 Bionor Immuno As Peptides derived from viral proteins for use as immunogens and dosage reactants
EP2679596B1 (de) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 Env-proteinvariante
US10450343B2 (en) 2013-03-21 2019-10-22 Sanofi-Aventis Deutschland Gmbh Synthesis of cyclic imide containing peptide products
HUE034308T2 (en) 2013-03-21 2018-02-28 Sanofi Aventis Deutschland Preparation of hydantoin-containing peptide products
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
EP2873423B1 (de) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (de) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
US11980663B2 (en) 2015-07-08 2024-05-14 American Gene Technologies International Inc. HIV pre-immunization and immunotherapy
US10137144B2 (en) 2016-01-15 2018-11-27 American Gene Technologies International Inc. Methods and compositions for the activation of gamma-delta T-cells
IL297238B2 (en) 2016-01-15 2024-08-01 American Gene Tech Int Inc Methods and preparations for gamma-delta T-cell activation
JP7153332B2 (ja) 2016-02-08 2022-10-14 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド Hivワクチン接種および免疫療法
ES2911448T3 (es) 2016-03-09 2022-05-19 American Gene Tech Int Inc Vectores combinados y métodos para el tratamiento del cáncer
WO2017213697A1 (en) 2016-06-08 2017-12-14 American Gene Technologies International Inc. Non-integrating viral delivery system and methods related thereto
CA3028982A1 (en) 2016-07-08 2018-01-11 American Gene Technologies International Inc. Hiv pre-immunization and immunotherapy
WO2018017882A1 (en) 2016-07-21 2018-01-25 American Gene Technologies International Inc. Viral vectors for treating parkinson's disease
US11820999B2 (en) 2017-04-03 2023-11-21 American Gene Technologies International Inc. Compositions and methods for treating phenylketonuria
US12559769B2 (en) 2017-06-16 2026-02-24 American Gene Technologies International Inc. Methods and compositions for the activation of tumor cytotoxicity via human gamma-delta t-cells
EP3876952A4 (de) 2018-11-05 2022-08-24 American Gene Technologies International Inc. Vektorsystem zur expression von regulatorischer rna
RU2727673C1 (ru) * 2019-08-09 2020-07-22 Федеральное государственное унитарное предприятие «Государственный научно-исследовательский институт особо чистых биопрепаратов» Федерального медико-биологического агентства Антитела против белка р17 ВИЧ-1 субтипа А
GB2610556B (en) * 2021-09-02 2026-07-08 113 Botanicals Ltd Solvent extraction of cannabaceae plant material

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ235538A (en) 1989-10-12 1992-06-25 Viral Technologies Inc Peptides immunoreactive with antibodies to hiv p17; carrier-bound peptides, vaccines, immunoassay and a method for forming antibody enriched sera
SE468168B (sv) 1990-02-20 1992-11-16 Replico Medical Ab Hiv-1, p24 peptider, diagnostiska antigener och foerfarande foer saerskiljande diagnostik av preliminaert hiv-1 positiva serumprov
DE4039925A1 (de) 1990-12-14 1992-06-17 Behringwerke Ag Ausgewaehlte peptide des gruppenspezifischen antigens (gag) von humanem immundefizienzvirus (hiv), ihre herstellung und verwendung
SE9101863D0 (sv) * 1991-06-13 1991-06-13 Replico Medical Ab Peptider, diagnostiskt antigen, vaccinkomposition och foerfarande foer selektering av hiv-stammar
US6525173B1 (en) 1997-01-02 2003-02-25 Universidade Federal De Minas Gerais Process for expression and production of recombinant protein hybrid protein (p24/p17) derived from human immunodeficiency viruses (HIV-1)
GB9703802D0 (en) 1997-02-24 1997-04-16 Kingsman Susan M Anti-hiv peptides and proteins
US5972339A (en) * 1997-11-13 1999-10-26 The General Hospital Corporation Method of eliciting anti-HIV-1 helper T cell responses
US6534482B1 (en) 1998-05-13 2003-03-18 Epimmune, Inc. Expression vectors for stimulating an immune response and methods of using the same
NO311807B1 (no) * 1999-03-04 2002-01-28 Bionor Immuno As HIV-peptider, antigener, vaksinepreparater, immunoassay- testsett og en metode for påvisning av antistoffer fremkalt av HIV

Also Published As

Publication number Publication date
NO314588B1 (no) 2003-04-14
EP1878742A3 (de) 2008-04-30
US20040115615A1 (en) 2004-06-17
AR033998A1 (es) 2004-01-21
WO2002020554A3 (en) 2002-06-13
CN1282656C (zh) 2006-11-01
NO20004413D0 (no) 2000-09-04
BR0114036A (pt) 2003-07-22
CN101104636A (zh) 2008-01-16
JP2004508381A (ja) 2004-03-18
HUP0303134A2 (hu) 2005-03-29
EP1878742A2 (de) 2008-01-16
NZ524556A (en) 2005-01-28
NZ535148A (en) 2007-06-29
ZA200301740B (en) 2004-06-21
HK1059940A1 (en) 2004-07-23
EP1322665A2 (de) 2003-07-02
EA200300336A1 (ru) 2003-08-28
AU2007202739B2 (en) 2009-12-03
CN1460111A (zh) 2003-12-03
AU8270601A (en) 2002-03-22
NO20004413L (no) 2002-03-05
MY136081A (en) 2008-08-29
SK287917B6 (sk) 2012-03-02
AU2007202739A1 (en) 2007-07-05
SK4022003A3 (en) 2003-09-11
US7009037B2 (en) 2006-03-07
CA2421193A1 (en) 2002-03-14
AR071262A2 (es) 2010-06-09
WO2002020554A2 (en) 2002-03-14
EA006308B1 (ru) 2005-10-27
HUP0303134A3 (en) 2012-09-28
US7612168B2 (en) 2009-11-03
ES2312465T3 (es) 2009-03-01
JP2011219481A (ja) 2011-11-04
AU2001282706B2 (en) 2007-03-22
US20070237783A1 (en) 2007-10-11
EP1322665B1 (de) 2008-08-27
DE60135564D1 (de) 2008-10-09

Similar Documents

Publication Publication Date Title
DE60135564D1 (de) Hiv-peptide aus konservierten regionen in gag p17 und deren anwendung z.b. in impfstoffen
ZA200407868B (en) 17alpha-Alkyl-17beta-oxy-estratrienes, uses thereof and pharmaceutical preparations.
TR200202194T2 (tr) Poliglütamik asit-kamptotesin birleşikleri ve hazırlama yöntemleri
BR0115810B1 (pt) composições cosméticas, dermatológicas e farmacêuticas isentas de tensoativos.
BR0210005B1 (pt) Polímero, processo para o preparo do mesmo e estrutura absorvente.
MXPA02007478A (es) Vacuna contra el virus de inmunodeficiencia humana.
EE200300544A (et) 4-anilinokinoliin-3-karboksamiidid, nende kasutamine ning valmistamine
DE60117859D1 (de) HARNSTOFFSUBSTITUIERTE IMIDAZOCHINOLINETHER und Arzneimittel, die diese umfassen.
ATE289640T1 (de) Amidofunktionelle aminopolydiorganosiloxane
BR0112962B1 (pt) Composições farmacêuticas compreendendo ácido hialurônico, ácido glicirretínico e polivinilpirrolidona, e uso desses compostos na preparação de medicamentos
DE60236099D1 (de) Druckverfahren, druckerzeugnisse und drucksteuerung
DE60131432D1 (de) Hiv-peptide aus tat-, rev- und wef-konservierten regionen und deren anwendung z.b. als impfstoffkomponenten
ITRM20030363A0 (it) Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico diesse.
BR0109367B1 (pt) pasta dispersante para a preparação de spandex, spandex e processo para a preparação do mesmo.
IT1321052B1 (it) Perfezionamenti in, o relativi a, attenuatori e dispositiviamplificatori.
EP1456376A4 (de) Neue chimäre rev-, tat- und nef-antigene
DE60113556T2 (de) Applikator, z.b. für rasierpräparate und dergleichen
DE50213606D1 (de) Zylinder im Falzapparat
JP2002275230A5 (de)
GB0217548D0 (en) Four human zinc-finger-containing proteins:MDZ3.MDZ4,MDZ7 and MDZ12
IT1318578B1 (it) Articolatore, particolarmente per le applicazioni in odontoiatria eodontotecnica.
ITRM20010116A0 (it) Indicatore goniometricoastronomico, in particolare solare e/o lunare.
DE50107204D1 (de) 8beta-substituierte-11beta-pentyl-und 11beta-hexyl-estra-1,3,5(10)-trienderivate
DK1423429T3 (da) Antistoffer mod caspase-8 og deres fremstilling og anvendelse
IL157753A0 (en) Natural antibody active against hiv virus

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties